Apac
  • Home
  • CXO Insights
  • CIO Views
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • About us
Apac
  • Admired Tech

    Agile

    AI Healthcare

    Artificial Intelligence

    Augmented Reality

    Aviation

    Big Data

    Blockchain

    Cloud

    Cryptocurrency

    Cyber Security

    DevOps

    Digital Transformation

    Drone

    HPC

    Infrared

    Internet of Things

    IT Services

    Marine Tech

    Networking

    PropTech

    Remote Work

    Robotics

    Scheduling Software

    Sensor Tech

    Simulation

    Smart City

    Software Testing

    Startup

    Storage

    Unified Communication

    Web Development

    Wireless

  • Automotive

    Banking

    Capital Market

    Construction

    E-Commerce

    Education

    FinTech

    Food and Beverages

    Gov and Public

    Healthcare

    Insurance

    Legal

    Logistics

    Manufacturing

    Media and Entertainment

    Metals and Mining

    Pharma and Life Science

    Retail

    Sports

    Travel and Hospitality

  • CISCO

    Google

    IBM

    Microsoft

    Oracle

    Salesforce

    SAP

    ServiceNow

  • Business Intelligence

    CEM

    Cloud-based Planning

    Cognitive

    Collaboration

    Compliance

    Contact Center

    Contact Tracing

    Contactless Payments

    Corporate Finance

    CRM

    Custom Software Development

    Data Center

    Digital Signage

    Enterprise Architecture

    Enterprise Asset Management

    Enterprise Communications

    Enterprise Contract Management

    Enterprise Performance Management

    ERP

    Facility Management

    Field Service

    Fleet Management

    Gamification

    HR Technology

    IT Infrastructure

    IT Service Management

    Managed Services

    PLM

    Procurement

    Product Management

    Project Management

    RegTech

    Revenue Management

    Sales Tech

Menu
    • CISCO
    • Collaboration
    • Compliance
    • Contact Center
    • Healthcare
    • IT Service Management
    • Microsoft
    • Retail
    • MORE
    #

    Apac CIO Outlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIO Outlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    • News
    • Biotech
    Editor's Pick (1 - 4 of 8)
    left
    Framework of Three Horizons to Manage Current and Future Growth

    Clark Golestani, VP & CIO, Merck

    The Changing Role of CIO in the Biopharmaceutical Industry

    Andy Newsom, CIO, CSL Behring

    Formula Five For Biotech IT

    Jeffrey Keisling, CIO and SVP, Pfizer

    Finding Answers in R&D Data is a Team Sport

    Dan Hausman,

    Plant Biotechnology Success Requires Collaboration, Proactive Strategy

    Tim Hassinger, President and CEO, Dow AgroSciences

    The Biotech IT PMO 2.0

    Paul Ritchie,

    The Biotech CIO Roadmap in a Sea of Change

    Amit Shah, VP of IT- Enterprise Applications & Systems, Excelitas Technologies

    The Internet of Things in Healthcare:Smart Strategies to Deliver Better Value

    Miguel Louzan, VP-IT, UCB, Inc.

    right

    Antengene Secures USD 97 Million in Series C Round of Financing

    By Apac CIO Outlook | Wednesday, July 22, 2020
    Tweet

    The company will use the proceeds from the investment round to fund the continuing clinical development of its robust pipeline of hematology and oncology therapies, expanding in-house research and development capabilities

    FREMONT, CA: Leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, Antengene Corporation, secured USD 97 million in a Series C funding round led by Fidelity Management & Research Company LLC, with participation from new investors including GL Ventures (an affiliate of Hillhouse Capital), GIC, and a large, reputable long-term investor. The round was also participated by existing investors Qiming Venture Partners and Boyu Capital.

    "We appreciate the recognition and trust from these prestigious investment institutions. This round of financing has drawn support from among the world's world's largest asset managers, top-tier healthcare investors widely recognized in the capital markets, and strong continuous support from our existing investors. This is an important milestone to reinforce Antengene's capabilities to bring cutting-edge therapies to help patients with life-threatening diseases in the Asia Pacific regions and around the world." said Dr. Jay Mei, Founder, Chairman, and CEO of Antengene.

    The company will use the proceeds from the investment round to fund the continuing clinical development of Antengene's robust pipeline of hematology and oncology therapies, expanding in-house research and development capabilities and strengthening the commercial infrastructures in APAC markets. The company has successfully made progress with its broad pipeline of six clinical-stage programs and six pre-clinical stage oncology assets.

    ATG-010 (selinexor) is the first and only oral selective inhibitor of nuclear export (SINE) compound in the world. The U.S. FDA approved selinexor combined with low-dose dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM). ATG-008 (onatasertib) is a second-generation dual mTORC1/2 inhibitor presently studied in multi-regional clinical trials for the treatment of advanced hepatocellular carcinoma (HCC), as well as non-small-cell lung cancer (NSCLC), gynecological malignancies and other cancers as a single agent or in combination with an anti-PD-1 antibody.

    ATG-016 (eltanexor) is a second-generation oral selective inhibitor of nuclear export protein XPO1 presently studied in myelodysplastic syndrome (MDS) as well as various types of solid tumors, such as colorectal cancer (CRC) and prostate cancer (PrC). The company's drug discovery team is also focused on the research and pre-clinical development of innovative small molecules, monoclonal, and bi-specific antibodies to treat cancer.

    tag

    Oncology

    Weekly Brief

    loading
    ON THE DECK

    Content Management System 2020

    Top Vendors

    Contactless Payments 2020

    Top Vendors

    Admired Tech 2020

    Top Vendors

    Previous Next

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    Leveraging CRM to Transform Leads Into Customers

    Leveraging CRM to Transform Leads Into Customers

    Major IoT Software Implementation Challenges

    Major IoT Software Implementation Challenges

    Key Advantages of Using Smart Home Technologies

    Key Advantages of Using Smart Home Technologies

    The Relevance of LMS in Education

    The Relevance of LMS in Education

    Advantages of Using the Microsoft Office Suite for Businesses

    Advantages of Using the Microsoft Office Suite for Businesses

    Three Shopping Trends in Fashion Industry

    Three Shopping Trends in Fashion Industry

    Loading...

    Copyright © 2021 APAC CIOoutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy Policy  |  Sitemap |  Subscribe

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/antengene-secures-usd-97-million-in-series-c-round-of-financing-nwid-7601.html